Clinical trial · Observational
DNA Cytometry for Cervical Cancer Screening in China
Comparison of DNA Image Cytometry and Conventional Cytology for Cervical Cancer Screening in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Very few screenings of any kind will be possible during a woman's lifetime in most low-resource regions, where 80% of the half-million global cases of cervical cancer occur every year. Although a single round of human papillomavirus (HPV) testing was associated with a significant decline in the rate of advanced cervical cancers and associated deaths, whether other methods like as DNA image cytometry can be used as an more accurate means than others in screening cervical cancer or not is yet to be verified. In addition, the accuracy of both DNA image cytometry and conventional cytology is not well known. The investigators hypothesized that DNA image cytometry was superior in screening cervical cancer than conventional cytology.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Subjects underwent cervical sample DNA image cytometry
- label
- 2
- description
- Subjects underwent cervical sample conventional cytology
Primary outcomes (1)
- measure
- The incidence of cervical cancer.
- timeFrame
- From the testing performed by the investigator (0h) to one year follow-up period
Secondary outcomes (3)
- measure
- The rate of death.
- timeFrame
- One year follow-up period after screening.
- measure
- The incidence of cervical intraepithelial neoplasia.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Currently or had been married * Not pregnant * Had an intact uterus with no prolapse * Had no history of cervical cancer * Living in China Exclusion Criteria: * Not willing to participate or finish the study at any time * History of cervical surgeries
References
Publications (1)
- RESULTTong H, Shen R, Wang Z, Kan Y, Wang Y, Li F, Wang F, Yang J, Guo X; Mass Cervical Cancer Screening Regimen Group. DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): a prospective randomized, controlled trial. Clin Cancer Res. 2009 Oct 15;15(20):6438-45. doi: 10.1158/1078-0432.CCR-09-1689. Epub 2009 Oct 13. PMID 19825960